Does the media favor GEHC or GKOS?

In the previous week, Glaukos had 2 more articles in the media than GE HealthCare Technologies. MarketBeat recorded 14 mentions for Glaukos and 12 mentions for GE HealthCare Technologies. GE HealthCare Technologies' average media sentiment score of 0.96 beat Glaukos' score of 0.89 indicating that GE HealthCare Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GE HealthCare Technologies 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 6 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer PHG or GKOS?

Glaukos has a consensus target price of $151.62, indicating a potential downside of 0.84%. Given Glaukos' stronger consensus rating and higher possible upside, analysts clearly believe Glaukos is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Koninklijke Philips 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Glaukos 1 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.80

Which has preferable valuation and earnings, PHG or GKOS?

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Koninklijke Philips $20.17B 1.34 $1.01B $1.17 23.55 Glaukos $507.44M 17.70 -$187.69M -$3.28 N/A

Does the media prefer PHG or GKOS?

In the previous week, Glaukos had 12 more articles in the media than Koninklijke Philips. MarketBeat recorded 14 mentions for Glaukos and 2 mentions for Koninklijke Philips. Glaukos' average media sentiment score of 0.89 beat Koninklijke Philips' score of 0.00 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Koninklijke Philips 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Glaukos 6 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ZBH or GKOS?

Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zimmer Biomet $8.23B 2.06 $705.20M $3.85 22.77 Glaukos $507.44M 17.70 -$187.69M -$3.28 N/A

Is ZBH or GKOS more profitable?

Zimmer Biomet has a net margin of 9.05% compared to Glaukos' net margin of -34.34%. Zimmer Biomet's return on equity of 13.24% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Zimmer Biomet 9.05% 13.24% 7.28% Glaukos -34.34% -6.92% -5.25%

Does the media prefer ZBH or GKOS?

In the previous week, Glaukos had 8 more articles in the media than Zimmer Biomet. MarketBeat recorded 14 mentions for Glaukos and 6 mentions for Zimmer Biomet. Glaukos' average media sentiment score of 0.89 beat Zimmer Biomet's score of 0.86 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 6 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, SOLV or GKOS?

Solventum has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solventum $8.33B 1.57 $1.56B $8.16 9.23 Glaukos $507.44M 17.70 -$187.69M -$3.28 N/A

Is SOLV or GKOS more profitable?

Solventum has a net margin of 17.33% compared to Glaukos' net margin of -34.34%. Solventum's return on equity of 23.51% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Solventum 17.33% 23.51% 7.63% Glaukos -34.34% -6.92% -5.25%

Does the media prefer SOLV or GKOS?

In the previous week, Glaukos had 12 more articles in the media than Solventum. MarketBeat recorded 14 mentions for Glaukos and 2 mentions for Solventum. Glaukos' average media sentiment score of 0.89 beat Solventum's score of 0.00 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Glaukos 6 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, SNN or GKOS?

Smith & Nephew SNATS has higher revenue and earnings than Glaukos. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 2.07 $625M N/A N/A Glaukos $507.44M 17.70 -$187.69M -$3.28 N/A

Does the media favor SNN or GKOS?

In the previous week, Glaukos had 11 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 14 mentions for Glaukos and 3 mentions for Smith & Nephew SNATS. Glaukos' average media sentiment score of 0.89 beat Smith & Nephew SNATS's score of 0.00 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Glaukos 6 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Glaukos (GKOS) Competitors

$152.89 +2.24 (+1.49%)

Closing price 07/8/2026 03:59 PM Eastern

Extended Trading

$153.05 +0.16 (+0.10%)

As of 07/8/2026 04:24 PM Eastern

Compare

GKOS vs. GEHC, PHG, ZBH, SOLV, and SNN

Should you buy Glaukos stock or one of its competitors? MarketBeat compares Glaukos with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Glaukos include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Solventum (SOLV), and Smith & Nephew SNATS (SNN). These companies are all part of the "medical equipment" industry.

How does Glaukos compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

82.1% of GE HealthCare Technologies shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 0.4% of GE HealthCare Technologies shares are held by company insiders. Comparatively, 5.9% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

GE HealthCare Technologies presently has a consensus target price of $79.71, indicating a potential upside of 23.24%. Glaukos has a consensus target price of $151.62, indicating a potential downside of 0.84%. Given GE HealthCare Technologies' higher possible upside, equities analysts clearly believe GE HealthCare Technologies is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GE HealthCare Technologies	0 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.50
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

GE HealthCare Technologies has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

GE HealthCare Technologies has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GE HealthCare Technologies	$20.63B	1.43	$2.08B	$4.18	15.47
Glaukos	$507.44M	17.70	-$187.69M	-$3.28	N/A

In the previous week, Glaukos had 2 more articles in the media than GE HealthCare Technologies. MarketBeat recorded 14 mentions for Glaukos and 12 mentions for GE HealthCare Technologies. GE HealthCare Technologies' average media sentiment score of 0.96 beat Glaukos' score of 0.89 indicating that GE HealthCare Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GE HealthCare Technologies	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	6 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GE HealthCare Technologies has a net margin of 9.10% compared to Glaukos' net margin of -34.34%. GE HealthCare Technologies' return on equity of 20.46% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GE HealthCare Technologies	9.10%	20.46%	5.73%
Glaukos	-34.34%	-6.92%	-5.25%

Summary

GE HealthCare Technologies beats Glaukos on 9 of the 16 factors compared between the two stocks.

How does Glaukos compare to Koninklijke Philips?

Koninklijke Philips (NYSE:PHG) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Glaukos has a consensus target price of $151.62, indicating a potential downside of 0.84%. Given Glaukos' stronger consensus rating and higher possible upside, analysts clearly believe Glaukos is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Koninklijke Philips has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

13.7% of Koninklijke Philips shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 5.9% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Glaukos had 12 more articles in the media than Koninklijke Philips. MarketBeat recorded 14 mentions for Glaukos and 2 mentions for Koninklijke Philips. Glaukos' average media sentiment score of 0.89 beat Koninklijke Philips' score of 0.00 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	6 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Koninklijke Philips has a net margin of 5.49% compared to Glaukos' net margin of -34.34%. Koninklijke Philips' return on equity of 13.51% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Koninklijke Philips	5.49%	13.51%	5.48%
Glaukos	-34.34%	-6.92%	-5.25%

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Koninklijke Philips	$20.17B	1.34	$1.01B	$1.17	23.55
Glaukos	$507.44M	17.70	-$187.69M	-$3.28	N/A

Summary

Glaukos beats Koninklijke Philips on 8 of the 15 factors compared between the two stocks.

How does Glaukos compare to Zimmer Biomet?

Zimmer Biomet (NYSE:ZBH) and Glaukos (NYSE:GKOS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

88.9% of Zimmer Biomet shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by company insiders. Comparatively, 5.9% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Zimmer Biomet has a net margin of 9.05% compared to Glaukos' net margin of -34.34%. Zimmer Biomet's return on equity of 13.24% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Glaukos	-34.34%	-6.92%	-5.25%

Zimmer Biomet has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	2.06	$705.20M	$3.85	22.77
Glaukos	$507.44M	17.70	-$187.69M	-$3.28	N/A

In the previous week, Glaukos had 8 more articles in the media than Zimmer Biomet. MarketBeat recorded 14 mentions for Glaukos and 6 mentions for Zimmer Biomet. Glaukos' average media sentiment score of 0.89 beat Zimmer Biomet's score of 0.86 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	6 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zimmer Biomet currently has a consensus price target of $102.33, indicating a potential upside of 16.75%. Glaukos has a consensus price target of $151.62, indicating a potential downside of 0.84%. Given Zimmer Biomet's higher possible upside, research analysts plainly believe Zimmer Biomet is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Zimmer Biomet beats Glaukos on 9 of the 17 factors compared between the two stocks.

How does Glaukos compare to Solventum?

Solventum (NYSE:SOLV) and Glaukos (NYSE:GKOS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

In the previous week, Glaukos had 12 more articles in the media than Solventum. MarketBeat recorded 14 mentions for Glaukos and 2 mentions for Solventum. Glaukos' average media sentiment score of 0.89 beat Solventum's score of 0.00 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	6 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.0% of Glaukos shares are owned by institutional investors. 0.2% of Solventum shares are owned by insiders. Comparatively, 5.9% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Solventum has a net margin of 17.33% compared to Glaukos' net margin of -34.34%. Solventum's return on equity of 23.51% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Glaukos	-34.34%	-6.92%	-5.25%

Solventum presently has a consensus target price of $83.50, indicating a potential upside of 10.90%. Glaukos has a consensus target price of $151.62, indicating a potential downside of 0.84%. Given Solventum's higher possible upside, analysts clearly believe Solventum is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.43
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Solventum has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.57	$1.56B	$8.16	9.23
Glaukos	$507.44M	17.70	-$187.69M	-$3.28	N/A

Solventum has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

Summary

Solventum and Glaukos tied by winning 8 of the 16 factors compared between the two stocks.

How does Glaukos compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and Glaukos (NYSE:GKOS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by insiders. Comparatively, 5.9% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Smith & Nephew SNATS has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

Smith & Nephew SNATS currently has a consensus target price of $30.93, indicating a potential upside of 3.09%. Glaukos has a consensus target price of $151.62, indicating a potential downside of 0.84%. Given Smith & Nephew SNATS's higher possible upside, equities analysts clearly believe Smith & Nephew SNATS is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Glaukos had 11 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 14 mentions for Glaukos and 3 mentions for Smith & Nephew SNATS. Glaukos' average media sentiment score of 0.89 beat Smith & Nephew SNATS's score of 0.00 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	6 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Smith & Nephew SNATS has higher revenue and earnings than Glaukos.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.07	$625M	N/A	N/A
Glaukos	$507.44M	17.70	-$187.69M	-$3.28	N/A

Smith & Nephew SNATS has a net margin of 0.00% compared to Glaukos' net margin of -34.34%. Smith & Nephew SNATS's return on equity of 0.00% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Glaukos	-34.34%	-6.92%	-5.25%

Summary

Glaukos beats Smith & Nephew SNATS on 8 of the 14 factors compared between the two stocks.

Get Glaukos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GKOS vs. The Competition

Export

Metric	Glaukos	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$8.85B	$7.55B	$7.00B	$23.55B
Dividend Yield	N/A	1.30%	2.67%	4.01%
P/E Ratio	-46.61	51.35	27.14	30.81
Price / Sales	17.70	80.71	534.05	21.17
Price / Cash	N/A	26.86	49.24	25.14
Price / Book	13.39	7.37	10.83	4.74
Net Income	-$187.69M	$159.19M	$3.56B	$1.07B
7 Day Performance	3.66%	-1.39%	-0.01%	-1.02%
1 Month Performance	20.66%	-2.43%	5.28%	0.91%
1 Year Performance	45.56%	0.61%	30.31%	15.73%

Glaukos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GKOS Glaukos	2.2542 of 5 stars	$152.89 +1.5%	$151.62 -0.8%	+49.1%	$8.85B	$507.44M	N/A	1,094	News Coverage Analyst Forecast Insider Trade
GEHC GE HealthCare Technologies	4.9213 of 5 stars	$65.05 -1.1%	$80.20 +23.3%	-14.0%	$29.91B	$20.63B	15.56	54,000	Positive News Analyst Forecast
PHG Koninklijke Philips	2.1751 of 5 stars	$27.20 +0.4%	N/A	+14.5%	$26.64B	$20.17B	23.30	65,340	News Coverage Analyst Upgrade
ZBH Zimmer Biomet	4.0965 of 5 stars	$91.25 -2.0%	$102.70 +12.6%	-6.2%	$18.01B	$8.23B	23.70	17,000	Analyst Forecast
SOLV Solventum	3.3382 of 5 stars	$78.21 -1.7%	$84.25 +7.7%	+0.3%	$13.77B	$8.33B	9.58	20,000	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GKOS) was last updated on 7/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Glaukos (GKOS) Competitors

GKOS vs. GEHC, PHG, ZBH, SOLV, and SNN

How does Glaukos compare to GE HealthCare Technologies?

Summary

How does Glaukos compare to Koninklijke Philips?

Summary

How does Glaukos compare to Zimmer Biomet?

Summary

How does Glaukos compare to Solventum?

Summary

How does Glaukos compare to Smith & Nephew SNATS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GKOS vs. The Competition

Glaukos Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Glaukos (GKOS) Competitors

GKOS vs. GEHC, PHG, ZBH, SOLV, and SNN

How does Glaukos compare to GE HealthCare Technologies?

Do institutionals and insiders believe in GEHC or GKOS?

Do analysts rate GEHC or GKOS?

Which has more risk and volatility, GEHC or GKOS?

Which has better earnings and valuation, GEHC or GKOS?

Does the media favor GEHC or GKOS?

Is GEHC or GKOS more profitable?

Summary

How does Glaukos compare to Koninklijke Philips?

Do analysts prefer PHG or GKOS?

Which has more risk & volatility, PHG or GKOS?

Do insiders and institutionals believe in PHG or GKOS?

Does the media prefer PHG or GKOS?

Is PHG or GKOS more profitable?

Which has preferable valuation and earnings, PHG or GKOS?

Summary

How does Glaukos compare to Zimmer Biomet?

Do insiders and institutionals hold more shares of ZBH or GKOS?

Is ZBH or GKOS more profitable?

Which has more risk and volatility, ZBH or GKOS?

Which has preferable valuation & earnings, ZBH or GKOS?

Does the media prefer ZBH or GKOS?

Do analysts recommend ZBH or GKOS?

Summary

How does Glaukos compare to Solventum?

Does the media prefer SOLV or GKOS?

Do insiders and institutionals believe in SOLV or GKOS?

Is SOLV or GKOS more profitable?

Do analysts rate SOLV or GKOS?

Which has better earnings & valuation, SOLV or GKOS?

Which has more risk & volatility, SOLV or GKOS?

Summary

How does Glaukos compare to Smith & Nephew SNATS?

Do insiders and institutionals have more ownership in SNN or GKOS?

Which has more risk & volatility, SNN or GKOS?

Do analysts rate SNN or GKOS?

Does the media favor SNN or GKOS?

Which has higher valuation and earnings, SNN or GKOS?

Is SNN or GKOS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GKOS vs. The Competition

Glaukos Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools